Bionano Genomics, Inc. (NASDAQ: BNGO) shares were up 11.22% to 7.73 in the pre-market session after it announced that on that third day of its five-day Next-generation Cytogenomics Symposium, Bionano Genomics, Inc. (Nasdaq: BNGO) announced six Saphyr Users who shared their findings and interactions with the Saphyr optical genome mapping system (OGM) to analyze solid tumor genomes.
Sapphyr gives a description of the structural variation in the genome for the first time and offers the chance to identify new cancer generators, therapeutic priorities, and prognostic markers, as was not feasible with the subsequent generation sequencing (NGS) and array systems before now.
- Marathon Patent Group (MARA) to stay in action aligned with the Bitcoin Market
- Is Zomedica Corp. (ZOM) a Buy with the Recent Dip?
Bionano provides tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and professional diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system enables researchers and clinicians to detect structural variations in cells or as part of a clinical trial that can be used for diagnostics and therapeutics.